SG Americas Securities LLC Boosts Stake in Jazz Pharmaceuticals PLC $JAZZ

SG Americas Securities LLC lifted its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 46.8% in the first quarter, HoldingsChannel.com reports. The fund owned 199,705 shares of the specialty pharmaceutical company’s stock after acquiring an additional 63,681 shares during the quarter. SG Americas Securities LLC’s holdings in Jazz Pharmaceuticals were worth $37,754,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JAZZ. Diversified Trust Co purchased a new stake in Jazz Pharmaceuticals during the first quarter valued at about $335,000. Hsbc Holdings PLC purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth about $858,000. Corient Private Wealth LLC increased its position in shares of Jazz Pharmaceuticals by 91.1% during the 4th quarter. Corient Private Wealth LLC now owns 10,200 shares of the specialty pharmaceutical company’s stock valued at $1,734,000 after purchasing an additional 4,863 shares during the last quarter. DGS Capital Management LLC bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $260,000. Finally, Pacer Advisors Inc. raised its holdings in shares of Jazz Pharmaceuticals by 19.8% during the 4th quarter. Pacer Advisors Inc. now owns 647,084 shares of the specialty pharmaceutical company’s stock valued at $110,004,000 after buying an additional 107,144 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

JAZZ has been the subject of several research reports. Barclays upped their target price on Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Bank of America boosted their price objective on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Wells Fargo & Company increased their target price on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $188.00 to $307.00 in a research report on Tuesday, May 19th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Sixteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $246.06.

Insider Buying and Selling

In other news, Director Rick E. Winningham sold 2,741 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total transaction of $662,143.37. Following the completion of the transaction, the director directly owned 9,567 shares in the company, valued at $2,311,100.19. This trade represents a 22.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Neena M. Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the completion of the transaction, the executive vice president directly owned 51,549 shares of the company’s stock, valued at $11,950,604.67. This trade represents a 2.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,098 shares of company stock worth $2,832,086 over the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $230.25 on Wednesday. The firm has a market cap of $14.46 billion, a PE ratio of -11,506.75, a price-to-earnings-growth ratio of 0.20 and a beta of 0.32. The company’s fifty day simple moving average is $222.61 and its two-hundred day simple moving average is $191.53. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a 12-month low of $105.00 and a 12-month high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The company had revenue of $1.07 billion during the quarter. As a group, equities analysts expect that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.